Analysts seem to be concerned about the uncertainties about whats next with COVID-19.


Key Points

  • The consensus analysts 12-month price target for BioNTech is roughly 25% below its current share price.
  • Wall Street analysts are pessimistic mainly because of the uncertainties about the recurring demand for COVID-19 vaccines.

BioNTech (NASDAQ:BNTX) might not be the best-known of the leading COVID-19 vaccine makers. The company has been largely overshadowed by its big partner Pfizer and by Moderna, at least in the U.S. However, BioNTech has been the biggest winner in the group so far this year with its shares skyrocketing more than 350%.

But that impressive gain could be a precarious one, based on analysts projections. Heres why Wall Street thinks BioNTech stock could sink 25% within the next 12 months.


Image source: Getty Images.

Pessimistic price target

The average 12-month price target for BioNTech stock right now is $261.95, roughly 25% lower than the current share price. That average is based on Refinitivs survey of 12 analysts.

Its not just that analysts havent been able to keep up with BioNTechs big gains and are behind the curve with increasing their price targets. Many on Wall Street dont appear to believe that the biotechs gains are sustainable.

BioNTech isnt the only vaccine stock that analysts are at least somewhat pessimistic about. The average 12-month price target for Pfizer is 11% below the current share price. Analysts are also bearish on Moderna, with an average price target 25% lower than the current price of the stock. 


Whats behind Wall Streets pessimism? More than anything, the lower price target for BioNTech reflects the uncertainties with COVID-19.

No one knows yet how strong demand will be for COVID-19 vaccines on an ongoing basis. A lot depends on the coronavirus itself. New variants could cause governments around the world to buy large quantities of vaccines on an annual basis for a long time to come. However, its also possible that COVID-19 could become a less serious concern, with vaccine demand declining relatively soon.

Analysts seem to believe the latter scenario is more likely. The average revenue estimate for BioNTech is a little lower in 2022 than it is for 2021. After 2022, analysts project a significant sales decline for COVID-19 vaccines.

There are also some concerns that the Pfizer-BioNTech vaccine might not be as competitive going forward as it has been so far. Several studies have found that the vaccines effectiveness against the delta variant wanes more quickly than rival vaccines. 

BioNTech doesnt have any other product on the market other than its COVID-19 vaccine. That status wont change anytime soon. The companys pipeline doesnt have any other late-stage programs right now. BioNTechs reliance on its COVID-19 vaccine magnifies analysts concerns about the potential for vaccine sales to slide in the not-too-distant future.

Looking on the bright side

Dont think that Wall Street has completely soured on BioNTech, though. Five analysts surveyed by Refinitiv still rate the stock as a buy or strong buy. Only one of the analysts in Refinitivs survey has a distinctly negative view of BioNTech. 

Bryan, Garnier & Co. even upgraded BioNTech from neutral to buy earlier this month. The investment firm set a price target that reflects a premium of nearly 19% above the biotechs current share price.  

Its also possible that BioNTech could shake up Wall Streets views with business development deals. BioNTech CEO Uğur Şahin stated in the companys Q2 conference call that BioNTech will certainly make some deals within the next 12 to 18 months.

Analysts tend to focus a lot more heavily on the short term than the long term. Even if BioNTech stock does fall as much as Wall Street expects over the next 12 months, it could still be a big winner over the long run.

Also, the uncertainties surrounding BioNTech work both ways. Although many analysts are skeptical that the demand for COVID-19 vaccines will remain near current levels, they could be wrong. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Keith Speights owns shares of Pfizer. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.


Motley Fool Returns

Stock Advisor S&P 500

614% 140%

Join Stock Advisor

Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Stock Advisor list price is $199 per year.

Stock Advisor launched in February of 2002. Returns as of 08/31/2021.

Cumulative Growth of a $10,000 Investment in Stock Advisor Calculated by Time-Weighted Return Motley

Related Articles

Contact us

Find us at the office

Trailor- Verkamp street no. 63, 81415 Zagreb, Croatia

Give us a ring

Dezha Manci
+38 695 645 231
Mon - Fri, 8:00-22:00

Reach out